- Home
- KEP vs GMAB Comparison
KEP vs GMAB Comparison
Compare KEP & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KEP
- GMAB
- Stock Information
- Founded
- KEP 1961
- GMAB 1999
- Country
- KEP South Korea
- GMAB Denmark
- Employees
- KEP N/A
- GMAB N/A
- Industry
- KEP Electric Utilities: Central
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- KEP Utilities
- GMAB Health Care
- Exchange
- KEP Nasdaq
- GMAB Nasdaq
- Market Cap
- KEP 17.8B
- GMAB 17.4B
- IPO Year
- KEP N/A
- GMAB N/A
- Fundamental
- Price
- KEP $12.70
- GMAB $32.69
- Analyst Decision
- KEP
- GMAB Strong Buy
- Analyst Count
- KEP 0
- GMAB 7
- Target Price
- KEP N/A
- GMAB $41.17
- AVG Volume (30 Days)
- KEP 401.0K
- GMAB 2.2M
- Earning Date
- KEP 11-11-2025
- GMAB 11-05-2025
- Dividend Yield
- KEP 0.38%
- GMAB N/A
- EPS Growth
- KEP 138.56
- GMAB 77.72
- EPS
- KEP 7.29
- GMAB 21.62
- Revenue
- KEP $70,790,610,836.00
- GMAB $3,646,881,232.00
- Revenue This Year
- KEP $4.89
- GMAB $24.25
- Revenue Next Year
- KEP $1.89
- GMAB $16.29
- P/E Ratio
- KEP $3.46
- GMAB $1.51
- Revenue Growth
- KEP 5.55
- GMAB 32.97
- 52 Week Low
- KEP $6.68
- GMAB $17.24
- 52 Week High
- KEP $15.19
- GMAB $33.63
- Technical
- Relative Strength Index (RSI)
- KEP 38.30
- GMAB 79.00
- Support Level
- KEP $12.70
- GMAB $28.36
- Resistance Level
- KEP $13.30
- GMAB $33.63
- Average True Range (ATR)
- KEP 0.16
- GMAB 0.61
- MACD
- KEP -0.05
- GMAB 0.22
- Stochastic Oscillator
- KEP 0.00
- GMAB 83.93
About KEP Korea Electric Power Corporation
Korea Electric Power Corp is an electric utility company in which the government of South Korea holds a controlling stake. The firm operates in the following segments: Transmission and distribution, Electric power generation (Nuclear), Electric power generation (Non-Nuclear), Plant maintenance & engineering service, and Others. The majority of the energy produced by the company comes from its nuclear and coal-fired assets. Korea Electric Power generates revenue through the Transmission and distribution segment. Geographically, it derives maximum revenue from Domestic operations.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.